ORAMED PHARMACEUTICALS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.28 USD | -0.87% |
|
-1.72% | -0.87% |
| 05-15 | Compugen Names David Silberman CFO | MT |
| 05-09 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechJoshua Hexter (Executives)Good morning, and welcome to Oramed Pharmaceuticals ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Calendar
09/07/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.3
USD
Average target price
4.25
USD
Spread / Average Target
+84.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.87% | 93.45M | |
| +63.37% | 62.59B | |
| -1.12% | 41.18B | |
| +44.76% | 40.29B | |
| -8.29% | 27.9B | |
| +13.05% | 26.21B | |
| -21.44% | 19.09B | |
| +5.32% | 13.08B | |
| +24.95% | 12.26B | |
| +28.39% | 12.05B |
- Stock Market
- Equities
- ORMP Stock
- News Oramed Pharmaceuticals Inc.
- Transcript : Oramed Pharmaceuticals Inc. - Special Call
